The ROI on pant-wearing and other social media tips
By Dr. Matthew Watson
For other things, however, the people around you have such high expectations you'll do them that you only lose points if you don't but gain very little if you do. For you, this may be true of the dishes. Certainly I've always maintained this is true for Valentine's Day. Get flowers and you simply maintain the relationship's status quo; fail to do anything and you lose big points fast.
"I can tell you without the slightest hesitation of conviction – having experienced it myself and seen it repeated countless times – is that active and successful social media engagement translates into:
- Unparalleled learning: accessing more information relevant to your discipline, specialty and company than you otherwise will.
- Enhanced profile: higher profile within your industry, profession, specialty and community. Social media is not the only way to build a profile but it can be very effective.
- Wider network: more touch points and meaningful relationships with people than you otherwise will accomplish by any other means combined."
- Traffic: "For companies, increased traffic equals increased opportunity to call readers/viewers to your intended action – interaction, citation, linking, investing, buying or engaging in some other action you solicit. For individual professionals, increased viewers translate into more chances for collaboration, citation, engagement, etc."
- Collaboration: "There is an intrinsic correlation between one’s profile and the opportunities one has for collaboration. For companies this means finding the right partnerships, joint ventures, strategic alliances, collaborators, employees, management and so on. For individual professionals, this means more and/or better quality invites to speak, write or collaborate in other ways. It also means finding quality grad students, faculty, employees and interns
- Revenue/Income: This is about translating a broader knowledge base and a wider network over which you have some level of influence (if only just that they are listening) into more money for your company, organization and yourself. For companies, this means finding the right partners, investors, customers and so on. For organizations this means finding the right donors, impressing the right grant reviewers and/or recruiting the right rain-maker faculty. For individual professionals this translates into promotions or job offers."
As I conclude my article I will conclude here:
"In order to create the kinds of perceptions and solicit the kinds of actions we want from the world around us, we must engage the world around us. The world around us is engaging online.
For all kinds of selfish and selfless reasons you, your company or organization and your career will benefit from you engaging there too."
and this prediction:
"...in less than the blink it took for the commercial world to accept websites and email, it will seem similarly ridiculous for professionals, academics and companies to operate and succeed without actively using social media."
____________
If this topic is of interest to you, here are some great resources particularly focused on the value of social media to those in life sciences.
Canaday, M. Is Life Science Social Media Worth It Yet? Three Tenets Behind Its Relevance To Your Business. Comprendia. 6 December 2012.
Bersenev A. Scientific blogging as a model for professional networking online. Cellular Therapy and Transplantation. 2010;2(7). 10.3205/ctt-2010-en-000084.01.
Bersenev, A. Scientific blogging as a model for professional networking online. 4 August 2010. StemCellAssays.com
Bersenev, A. Who’s Who in the Stem Cell Blogosophere. 27 June 2011. StemCellAssays.com
Bishop, D. How to bury your academic writing. Bishop’s Blog. 26 August 2012.
Buckler, L. If You’re Breathing, You’re in PR. Cell Therapy Blog. 11 June 2010.
Buckler, L. Don’t feel the pain of ignoring social media? Just wait a minute…. CellTherapyBlog.com 22 October 2008.
Jewell, T. Survey: How our scientists use social media. AZHealthConnections.com. 12 February 2012.
Knoepfer, P. Top ten tips for blogging for scientists. 2 August 2012. IPScell.com
Shipman, M. Why Scientists Should Publicize Their Findings – for Purely Selfish Reasons. Scientific America. Blog. 18 June 2012.
Shipman, M. A gentle introduction to Twitter for the apprehensive academic. Scientific America. Blog. 14 June 2011.
Small, G. Time to Tweet. Nature 2011. 479 141 2 November 2011
Wilcox, C. Social Media for Scientists Part 1: It’s Our Job. Scientific American Blog. 27 September 2011.
Wilcox, C. Social Media for Scientists Part 2: You Do Have time. Scientific American Blog. 29 September 2011.
Wilcox, C. Social Media for Scientists Part 3: Win-Win. Scientific American Blog. 10 October 2011.
Wilcox, C. Guest Editorial: It’s time to e-Volve. Taking Responsibility for Science Communication in a Digital Age. Biol Bull. 22285-87. (April 2012)
The Rules of Social Media. Fast Company. 8 August 2012.
Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/k7ANTnLXNjc/the-roi-on-pant-wearing-and-other.html
- 001 Stem cells for a Webby! [Last Updated On: April 28th, 2010] [Originally Added On: April 28th, 2010]
- 002 Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: April 30th, 2010] [Originally Added On: April 30th, 2010]
- 003 Google to Invest in Regenerative Medicine [Last Updated On: May 5th, 2010] [Originally Added On: May 5th, 2010]
- 004 Biotech tax credit appears perfectly designed for cell therapy companies to recoup research dollars spent in 2009-10 [Last Updated On: May 22nd, 2010] [Originally Added On: May 22nd, 2010]
- 005 The changing face of PR and why it matters to regenmed [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- 006 FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- 007 Careers in cell therapy & regenerative medicine [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 008 The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: January 15th, 2011] [Originally Added On: January 15th, 2011]
- 009 Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: February 12th, 2011] [Originally Added On: February 12th, 2011]
- 010 In vivo cell trafficking just took a leap forward [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- 011 Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: July 10th, 2011] [Originally Added On: July 10th, 2011]
- 012 Clinical trial costs [Last Updated On: July 31st, 2011] [Originally Added On: July 31st, 2011]
- 013 Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 14th, 2011] [Originally Added On: August 14th, 2011]
- 014 Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 015 Commercial-stage Cell Therapy Companies and Products [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 016 Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 017 Commercializing Cell-based Regenerative Medicines [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- 018 Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: November 27th, 2011] [Originally Added On: November 27th, 2011]
- 019 Active phase III or II/III cell therapy trials [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 020 Recently approved cell therapy products [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 021 Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 022 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: January 1st, 2012] [Originally Added On: January 1st, 2012]
- 023 Predicting the Success of the Late-Stage Cell-Based Cancer Immunotherapy Pipeline? [Last Updated On: March 11th, 2012] [Originally Added On: March 11th, 2012]
- 024 Another > $100M month for companies in the cell therapy space [Last Updated On: May 6th, 2012] [Originally Added On: May 6th, 2012]
- 025 Cell-based Cancer Immunotherapies. Some metrics.. [Last Updated On: May 20th, 2012] [Originally Added On: May 20th, 2012]
- 026 Industry-sponsored cardiovascular cell therapies. Some metrics. [Last Updated On: May 27th, 2012] [Originally Added On: May 27th, 2012]
- 027 Bioreactor Design and Bioprocess Controls for Industrialized Cell Processing [Last Updated On: June 17th, 2012] [Originally Added On: June 17th, 2012]
- 028 FDA 1. RSI 0. Regenerative Sciences (Regenexx) vs FDA (2012) [Last Updated On: July 29th, 2012] [Originally Added On: July 29th, 2012]
- 029 Is the cell therapy sector outperforming the major indices? [Last Updated On: August 12th, 2012] [Originally Added On: August 12th, 2012]
- 030 Are some cell counts too good to be true? Why some companies' product data may mislead. [Last Updated On: September 2nd, 2012] [Originally Added On: September 2nd, 2012]
- 031 Two lessons I learned this week. [Last Updated On: September 16th, 2012] [Originally Added On: September 16th, 2012]
- 032 The cost of clinical trial data bias/loss, FDA's new job and the need for bold leadership. [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- 033 Anticipated short-term cell therapy industry clinical milestones [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- 034 Cell therapy portfolio outperforms major indices year-to-date [Last Updated On: October 14th, 2012] [Originally Added On: October 14th, 2012]
- 035 CIRM addresses some tough questions. Is it all just glass towers and basic research? [Last Updated On: October 21st, 2012] [Originally Added On: October 21st, 2012]
- 036 GEN's "Cellular Therapy Wave Finally Cresting". An overview and data set. [Last Updated On: November 4th, 2012] [Originally Added On: November 4th, 2012]
- 037 Cell Therapy Industry Group Welcomes its 4,000th member [Last Updated On: November 11th, 2012] [Originally Added On: November 11th, 2012]
- 038 Six steps to fighting non-compliant cell therapy treatments. --- The stuff of grey shades, spades, ivory towers and (ahem) balls. [Last Updated On: December 2nd, 2012] [Originally Added On: December 2nd, 2012]
- 039 A proposed 6-step platform for the cell therapy industry to consider in combating non-compliant cell therapy treatments [Last Updated On: December 16th, 2012] [Originally Added On: December 16th, 2012]
- 040 The Accuracy of Adipose Stem Cell Doses [Last Updated On: December 23rd, 2012] [Originally Added On: December 23rd, 2012]
- 041 Cell Therapy Blog welcomes 2013 [Last Updated On: January 6th, 2013] [Originally Added On: January 6th, 2013]
- 042 2013 Annual Regenerative Medicine Industry Report [Last Updated On: April 21st, 2013] [Originally Added On: April 21st, 2013]
- 043 Commercialization of Regenerative Medicine: Learning from Spin-Outs [Last Updated On: April 28th, 2013] [Originally Added On: April 28th, 2013]
